12:00 AM
 | 
Dec 04, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Foscan temoporfin chlorin-based photodynamic therapy regulatory update

Following a meeting with the FDA, SOH said it will submit an amendment to its NDA for Foscan as a palliative treatment for head and neck cancer, for which the company...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >